Takeda, Amgen Sign Mega Japanese Deal
This article was originally published in PharmAsia News
Executive Summary
Amgen and Takeda Pharmaceutical have signed a deal worth up to $1.18 billion that provides Takeda with Japanese rights to up to 12 new biopharmaceuticals from Amgen's pipeline. In addition, Takeda will acquire Amgen's Japanese unit and receive worldwide rights to Amgen's experimental cancer therapy motesanib diphosphate. In return, Amgen will retain Japanese co-promotion rights and receive at least 10 percent royalties on sales in Japan. Takeda will pay Amgen $200 million up front and as much as $702 million in milestones for the 12 compounds, as well as $100 million up front for motesanib diphosphate and up to $175 million in milestones. The deal comes as Takeda looks to shore up its pipeline prior to patent expiration of best-selling diabetes drug Actos, and as Amgen struggles to regain its footing in the wake of safety concerns over its anemia franchise. (Click here for more